"Information is one of our greatest resources. PharmaTex Research, LLC conducts clinical studies and drug research to collect vital data about health, medicine and the human body. Our clinical research facility invites participants to help us in our research. You can aid the cause by volunteering for a clinical study today. Our multi-specialty clinical research facility is dedicated to collecting accurate and vital data for pharmaceutical research. Our goal is to provide treatment alternatives to patients in need while furthering pharmacological and device research, which will ultimately have a positive impact on our community at large."

During the past decade, PharmaTex Research conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 3 clinical trials were completed. i.e. 42.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PharmaTex Research" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Pfizer" with 2 trials sponsored, "Zoll Medical Corporation" with 2 trials sponsored, "American Regent, Inc." with 1 trials sponsored and "CSL Behring" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PharmaTex Research" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator and "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "PharmaTex Research" are "Heart Failure" (4 trials), "Cardiovascular Disease" (2 trials), "Acute Myocardial Infarction" (1 trials), "COVID-19" (1 trials) and "Cardiac Arrhythmia" (1 trials). Many other conditions were trialed in "PharmaTex Research" in a lesser frequency.

Most popular intervention types in "PharmaTex Research" are "Drug" (8 trials), "Device" (2 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Empagliflozin" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Arrhythmia Management System (AMS)" (1 trials) and "BI 767551 inhaled" (1 trials). Other intervention names were less common.

The vast majority of trials in "PharmaTex Research" are 11 trials for "All" genders.

Currently, there are NaN active trials in "PharmaTex Research". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 2 completed trials in PharmaTex Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in PharmaTex Research, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".